# Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

> **NCT00110500** · PHASE1 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Diabetic Neuropathy

## Interventions

- **GENETIC:** hVEGF-A

## Key facts

- **NCT ID:** NCT00110500
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110500, "Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00110500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*